Description:

E5103 24-months Post-Registration Cardiac Function Assessment Form NCT00433511 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8C9D1499-1276-D754-E040-BB89AD43467F

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8C9D1499-1276-D754-E040-BB89AD43467F

Keywords:
Versions (3) ▾
  1. 8/26/12
  2. 1/9/15
  3. 6/16/15
Uploaded on:

June 16, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

E5103 24-months Post-Registration Cardiac Function Assessment Form NCT00433511

Details

INSTRUCTIONS: Use this form ONLY when submitting results from the 24 months post-registration cardiac assessment. For any cardiac data obtained prior to the 24-month timepoint, please use the E5103 Cardiac Toxicity Form

Header
Report Period
Patient demographics
Cardiac Function
Has the patient had a documented assessment of cardiac function
Clinical Episode of CHF (requires symptoms associated with a decrease of LVEF to below LLN)
S3 Gallop
Bibasilar Rales
Cardiomegaly
Abnormal ECG
Cardiac Adverse Events
CTC Adverse Event Term
5 more items in the detailed view.
CTC AE Attribution Code
LVEF Information
Has the patient had a documented assessment of LVEF (this report period)
Method of Evaluation
%
%
Comments
Back to the top of the page 

Similar models